Nasdaq

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Monthly Prescribing Reference

Long-Term Data Show Octreotide SC Depot Safe, Effective for Acromegaly

Significant increases in biochemical response rates were observed in the overall population and in new patients. Treatment with CAM2029, an investigational once-monthly octreotide subcutaneous (SC) ...
Seeking Alpha

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
FOX8 Cleveland

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment ...
MedPage Today

Investigational Once-Monthly Injectable Boosts Response Rate in Acromegaly

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...
Nasdaq

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities PLD is ...
Monthly Prescribing Reference

First Generic Version of Sandostatin LAR Depot Now Available

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...
WDAF-TV

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
ascopubs.org

Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.

An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC). Background: Somatostatin receptor ...
ascopubs.org

Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central ...

Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma As administered in this study, octreotide did not decrease diarrhea during pelvic radiation ...
KTLA

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

LUND, Sweden, July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, ...